NEW YORK (GenomeWeb News) – Invitrogen and Applied Biosystems announced separately today that their respective shareholders have voted in favor of the firms’ $6.7 billion merger.
Both firms said that around 98 percent of their respective shares were cast in favor of the deal, which is expected to close next month. The transaction already has cleared US antitrust hurdles but still requires clearance from European Union regulators.
As reported by GenomeWeb Daily News on Oct. 9, Invitrogen increased its expectations for first-year post-merger cost synergies to $80 million from $60 million. It said today that it remains committed to achieving that goal.
Invitrogen also said that the current issues affecting capital markets are not anticipated to have an impact on financing for the deal.